Frequency and complications of chronic iridocyclitis in ANA-positive pauciarticular juvenile chronic arthritis.
Chronic iridocyclitis (CI) is among the most important extra-articular manifestations of juvenile chronic arthritis (JCA) and is most often observed in young girls with pauciarticular JCA and circulating antinuclear antibodies (ANAs). The frequency of CI found in 39 children with ANA-positive pauciarticular JCA was 56%. None of the patients developed ocular complications during follow-up. We think that this favourable outcome was primarily due to the early diagnosis and to our choice of using atropine as a mydriatic agent and to prolong atropine, after having spaced its administration further apart, up to one year or longer after the remission of ocular manifestations.
Gori
S
S
Department of Ophthalmology, University of Pavia, IRCCS S. Matteo, Italy.
Broglia
A M
AM
Ravelli
A
A
Aramini
L
L
Di Fuccia
G
G
Nicola
C A
CA
Martini
A
A
D000287:Administration, Topical; D000293:Adolescent; D017668:Age of Onset; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000276:immunology*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000276:immunology; D001285:Atropine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005128:Eye Diseases / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D007223:Infant; D015863:Iridocyclitis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D009883:Ophthalmic Solutions; D010894:Piroxicam / Q000627:therapeutic use; D012008:Recurrence
D000893:Anti-Inflammatory Agents; D000974:Antibodies, Antinuclear; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D010894:Piroxicam; D001285:Atropine